China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical trial approval from the US FDA for its investigational drug ZG006, intended to treat small-cell lung cancer and other solid tumors.
ZG006: A Tri-Specific Antibody Targeting CD3 and DLL3 Epitopes
ZG006 is a tri-specific antibody developed through the company’s bispecific antibody (BsAb)/multi-specific antibody platform. It targets CD3 and two different DLL3 epitopes, making it the world’s first tri-specific antibody (CD3×DLL3×DLL3) designed to target DLL3-expressing tumors. This innovative approach has the potential to revolutionize treatment options for patients with specific types of cancer.
Preclinical Studies Highlight ZG006’s Potential
Preclinical studies have demonstrated that ZG006 exhibits significant tumor inhibitory effects and possesses good safety characteristics. These findings provide a strong foundation for the advancement of ZG006 into clinical trials, which will further evaluate its efficacy and safety in treating small-cell lung cancer and other solid tumors.-Fineline Info & Tech
